Sovleplenib(HMPL-523),一种新型Syk抑制剂,用于中国原发免疫性血小板减少症患者:一项随机、双盲、安慰剂对照的1b/2期研究
这项在中国九家医院开展的随机、双盲、安慰剂对照1b/2期研究评估了Syk抑制剂sovleplenib在原发免疫性血小板减少症患者中的安全性、耐受性、药代动力学、初步活性及2期推荐剂量。45例患者随机分配接受sovleplenib(100、200、300或400 mg每日一次)或安慰剂治疗8周,随后16周开放标签sovleplenib治疗。2期推荐剂量为300 mg每日一次,该剂量组主要疗效终点达标比例为63%(95% CI 35-85),高于安慰剂组的9%(95% CI 0-41)。Sovleplenib耐受性良好,300 mg组在0-24周显示持久的缓解,为未来研究提供了证据。
要点
- 2期推荐剂量为sovleplenib 300 mg每日一次口服。
- 300 mg组主要疗效终点达标比例为63%(95% CI 35-85),安慰剂组为9%(95% CI 0-41)。
- 300 mg组0-24周总缓解率为80%(16/20),持续缓解率为31%(95% CI 11-59;5/16)。
核心结论
- Sovleplenib耐受性良好,2期推荐剂量在原发免疫性血小板减少症患者中显示出有前景的持久缓解,为未来研究提供了证据。
- 一项3期试验正在进行(NCT05029635),以确认sovleplenib在原发免疫性血小板减少症患者中的疗效和安全性。
研究设计与样本
- 这项随机、双盲、安慰剂对照的1b/2期研究在中国九家医院开展。
- eligible患者年龄18-75岁,ECOG体能状态评分0-1,原发免疫性血小板减少症病程超过6个月,且既往一线治疗无效或复发,或脾切除术后反应不佳或术后复发。
- 剂量递增阶段(100 mg、200 mg或300 mg口服每日一次)和剂量扩展阶段(2期推荐剂量)各包括一个8周双盲、安慰剂对照期,患者按3:1随机分配接受sovleplenib或安慰剂,随后进入16周开放标签sovleplenib治疗期。
- 2019年5月30日至2021年4月22日期间,62例患者接受资格评估,45例(73%)被随机分配。
- 8周双盲期内至少接受一剂研究药物的患者包括安慰剂组(n=11)和sovleplenib 100 mg组(n=6)、200 mg组(n=6)、300 mg组(n=16)、400 mg组(n=6);400 mg组是在前几个剂量未观察到方案规定的安全性事件后增加的。
主要发现
- 所有参与者均为亚洲人;45例中男性18例(40%),女性27例(60%);中位年龄40.0岁(IQR 33.0-50.0)。
- sovleplenib组34例中10例(29%)与安慰剂组11例中5例(45%)接受了 concomitant 抗原发免疫性血小板减少症治疗。
- 达到主要疗效终点的患者比例:100 mg组3例(50%;95% CI 12-88),200 mg组3例(50%;95% CI 12-88),300 mg组10例(63%;95% CI 35-85),400 mg组2例(33%;95% CI 4-78),安慰剂组1例(9%;95% CI 0-41)。
- 300 mg组总缓解率为80%(16/20,包括持续接受sovleplenib者及从安慰剂交叉者);0-24周持续缓解率在持续sovleplenib 300 mg组为31%(95% CI 11-59;5/16),在从安慰剂交叉至sovleplenib组为75%(95% CI 19-99;3/4)。
- 28天安全性评价期内,sovleplenib组发生2例2级或更差的治疗相关治疗中出现的不良事件(高甘油三酯血症和贫血)。
关键数值与推荐
- 主要疗效终点定义为0-8周内连续两次访视血小板计数达到30×10^9/L或以上且为基线的两倍,且未接受挽救治疗的患者比例。
- 2期推荐剂量确定为300 mg每日一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spleen tyrosine kinase (Syk) inhibitor is a treatment option for primary immune thrombocytopenia. We aimed to evaluate the safety, tolerability, pharmacokinetics, preliminary activity, and recommended phase 2 dose of sovleplenib in patients with primary immune thrombocytopenia. METHODS: This randomised, double-blind, placebo-controlled, phase 1b/2 study was conducted at nine hospitals in China. Eligible patients were aged 18-75 years, had an ECOG performance score of 0-1, had primary immune thrombocytopenia for more than 6 months, and did not respond or relapsed after previous first-line treatment or had poor response or postoperative relapse after a splenectomy. Dose-escalation (100 mg, 200 mg, or 300 mg given orally once a day) and dose-expansion phases (recommended phase 2 dose) each consisted of an 8-week, double-blind, placebo-controlled period in which patients were randomly assigned (3:1) to receive sovleplenib or placebo with an interactive web response system followed by a 16-week, open-label period with sovleplenib. Patients, investigators, and the sponsor were masked to treatment allocation during the first 8 weeks. The main efficacy endpoint was the proportion of patients whose platelet count reached 30 × 109 platelets per L or higher and was double of the baseline at two consecutive visits during 0-8 weeks without rescue therapy. Efficacy was evaluated by intention-to-treat. This study is registered with ClinicalTrials.gov, NCT03951623. FINDINGS: Between May 30, 2019, and April 22, 2021, 62 patients were assessed for eligibility and 45 (73%) were randomly assigned. Patients received at least one dose of the study drug during the 8-week double-blind period (placebo [n=11] and sovleplenib 100 mg [n=6], 200 mg [n=6], 300 mg [n=16], and 400 mg [n=6]; this group was added following the observation of no protocol-specified safety events at the previous doses). All participants were Asian; 18 (40%) of 45 were male and 27 (60%) were female. The median age was 40·0 years (IQR 33·0-50·0). Ten (29%) of 34 patients in sovleplenib groups versus five (45%) of 11 in the placebo group received concomitant anti-primary immune thrombocytopenia therapy. The recommended phase 2 dose was determined as 300 mg once a day. The proportion of patients who met the main efficacy endpoint were three (50%; 95% CI 12-88) in the 100 mg group, three (50%; 12-88) in the 200 mg group, ten (63%; 35-85) in the 300 mg group, and two (33%; 4-78) in the 400 mg group compared with one (9%; 0-41) in the placebo group. The overall response rate in the 300 mg group was 80% (16 of 20 who received continuous sovleplenib plus those who crossed over from placebo) and the durable response rate was 31% (11-59; five of 16) in the continuous sovleplenib 300 mg and 75% (19-99; three of four) crossed from placebo to sovleplenib during 0-24 weeks. During the 28-day safety evaluation period, two grade 2 or worse treatment-related treatment-emergent adverse events occurred in the sovleplenib groups (hypertriglyceridaemia and anaemia). During 0-8 weeks, the most frequent treatment-emergent adverse events were an increase in blood lactate dehydrogenase, haematuria, and urinary tract infection (seven [21%] of 34 in sovleplenib groups vs one [9%] of 11 in the placebo group); and occult blood-positive and hyperuricaemia (four [12%] vs three [27%] for each). No fatal treatment-emergent adverse events were recorded. INTERPRETATION: Sovleplenib was well tolerated, and the recommended phase 2 dose showed a promising durable response in patients with primary immune thrombocytopenia, which provides evidence for future investigations. A phase 3 trial is ongoing (NCT05029635) to confirm the efficacy and safety of sovleplenib in patients with primary immune thrombocytopenia. FUNDING: HUTCHMED.
引用
- Liu X, Zhou H, Hu Y, et al. Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study. Lancet Haematol. 2023. PMID: 37028433. doi:10.1016/S2352-3026(23)00034-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。